Biotechnology innovations are transforming key sectors such as health, agriculture, and the environment. From life-saving medicines to more resilient crops, biotechnology drives crucial advances for society. In this context, biotechnology patents play a fundamental role in protecting the future: they allow entrepreneurs and researchers to safeguard their inventions, encourage investment in new developments, and ensure that these innovations reach the market. In Europe, where collaboration between science and industry is a priority (for example, through the European Institute of Innovation and Technology, EIT, which promotes an environment conducive to innovation), understanding the patent system is key to unlocking the full potential of the biotechnology sector.
Below, we explore what biotechnology patents are, why they are strategic, how they are regulated in Europe, some notable examples, the ethical challenges they entail, and the role they will play in the future of vital sectors. We also offer recommendations for entrepreneurs and researchers to make the most of the patent system in this field.
Definition and Function of Patents in Biotechnology
A patent is a legal title that grants its holder exclusive rights to an invention for a limited time and within a limited territory. Simply put, a patent prevents third parties from manufacturing, using, or selling an invention without consent for 20 years (the typical term in Europe) from the date of application, generally within the country or countries where it has been granted. In the case of European patents, a single application filed with the European Patent Office (EPO) can extend protection to up to 38 member states of the European Patent Convention.
In the field of biotechnology, we refer to inventions related to biological material (e.g., genes, cells, microorganisms) or biological processes. The European Patent Convention defines “biotechnological inventions” as those relating to biological material (for example, a living organism or DNA) or a process for producing, processing, or using such material. This ranges from modified microorganisms to methods for manipulating cells or genetic sequences.
What is the purpose of patenting a biotechnological innovation?
Primarily, to protect and promote innovation. On the one hand, a patent provides an economic incentive: by granting exclusive rights, it offers inventors and companies the opportunity to recoup their investment in search and development. Economic studies have shown that many important innovations would not reach the market without patent protection. A clear example is the pharmaceutical industry, where a company would be unlikely to finance costly clinical trials without the guarantee of exclusivity provided by a patent.
On the other hand, patents also disseminate knowledge: to obtain a patent, the invention must be clearly described publicly, and that information is published (usually 18 months after the application) contributing to the global knowledge base. This balance—temporary exclusivity in exchange for disclosure—drives scientific progress by allowing other researchers to “stand on the shoulders of giants” and build upon previous advances. Patent databases, such as the EPO’s Espacenet, contain more than 60 million technical documents accessible free of charge, a valuable resource for new discoveries.
Biotechnology Patents: A Driver of Innovation and Investment
In a high-tech sector such as biotechnology, patents are of strategic importance. Ensuring the protection of an invention provides legal certainty and encourages investment in its development. Having protected intangible assets instills confidence in investors and business partners, as it ensures that the company will be able to commercially exploit its findings without direct competition for a certain period of time. In fact, protecting innovation is considered a fundamental tool for capitalizing on technological developments; the patent system fosters public-private collaboration on an equal footing and enhances the sector’s appeal to investors. In other words, a biotechnology start-up with a strong patent portfolio is much more attractive to venture capitalists and industrial partners, because patents give it a competitive advantage and the ability to monetize its products.
Key Advantages of Patents in Biotechnology
Among the specific advantages that biotechnology patents offer companies are:
- Protection of complex innovations: Biotechnology technologies—often the result of years of search (for example, a new gene therapy or an industrial enzyme)—are safeguarded from imitation by competitors. This allows for the exclusive commercial exploitation of the invention.
- Encouragement of long-term investment: With innovation protected, companies and research centers are encouraged to invest in long-lead-time, high-risk projects, knowing they will be able to reap the rewards in the market. Without patents, many projects (vaccines, biopharmaceuticals, etc.) would not obtain funding due to the risk of being copied.
- Return on R&D and Funding: The grant of patents makes it easier to obtain funding (public or private) and ensures a potential return on R&D investment. Banks and investment funds typically view patented technology favorably before financing its development or commercialization.
- Positioning and technological trademarking: Holding patents positions the company or research group as a leader in its field, strengthening its reputation. This can lead to more opportunities for collaboration, technology licensing to third parties, or expansion into new markets.
Clear Benefits
Thanks to these factors, committing to a solid patent strategy is, in the words of experts, investing in the future of science and global health. The data reflect this trend: biotechnology has become one of the fastest-growing fields in terms of patent applications. In recent decades, the biotechnology sector has consistently ranked among the top 10 technical fields with the most patent applications filed at the EPO, with approximately half of those applications coming from universities and public research centers.
Even at the national level, Spain, for example, broke records in 2024 with European patents: biotechnology and medical technology tied for second place in terms of the number of European patent applications (163 each), with biotechnology growing by nearly 9% compared to the previous year.
This dynamism demonstrates how patents are a driver of innovation, incentivizing both start-ups and large companies to invest in high-impact biotechnology solutions.
Legal Framework for Biotechnology Patents in Europe
Europe has a robust legal framework to protect biotechnology inventions, balancing incentives for innovation with ethical considerations. The central pillar is the European Patent Convention (EPC), a treaty that gave rise to the European Patent Organization and the European Patent Office (EPO). By filing an application with the EPO (headquartered in Munich), an inventor can obtain a European patent which, once granted, can be validated in up to 38 European EPC member countries. This greatly simplifies the process, eliminating the need to file patent applications country by country. Furthermore, since 2023, the EU has implemented the Unitary Patent, a new voluntary system that allows a single patent to provide uniform protection across numerous EU countries, reducing costs and administrative burdens for applicants (an option of particular interest to biotechnology companies given the international scope of their markets).
Which Inventions Are Patentable
Biotechnological inventions are, in essence, patentable in Europe provided they meet the general criteria for patentability: novelty, inventive step, and industrial applicability. However, there are limitations and exclusions defined in both the EPC and EU legislation to address ethical and public policy concerns. For example, the following cannot be patented in Europe (Art. 53 EPC and associated regulations):
- Inventions contrary to public order or morality: if commercial exploitation of the invention offends ethical values (for example, dangerous or immoral uses).
- Specific plant varieties or animal breeds: the law excludes protection for specific varieties, as these are protected by other means (in Europe, plant variety protection is provided by the CPVO, independent of patents).
- Essentially biological processes for the production of plants or animals: traditional breeding methods (crossbreeding and selection) are not patentable, to prevent the monopolization of conventional breeding techniques. Only methods that include additional technical or genetic steps are permitted (for example, the use of molecular markers or transgenesis).
- Medical or diagnostic methods for humans or animals: Clinical or surgical techniques applied to the body are not patentable as such (although devices or drugs used in them are).
- The human body at any stage of its development and human cloning processes: the entire human body and the mere discovery of parts thereof are excluded from patentability (for example, a gene that exists in nature is not patentable unless there is a technical application involved).
Directive 98/44/EC and Biotechnology Patents
To harmonize criteria, the European Union issued Directive 98/44/EC on the legal protection of biotechnological inventions. This directive, adopted in 1998 after intense debate, clarified what is and is not patentable in biotechnology and required all EU countries to adapt their national laws accordingly. For example, the directive confirmed that an isolated biological material (such as an isolated gene with a known function) may be patentable even if it exists in nature. It also made clear that genetically modified plants or animals may be patented provided that the claim is not limited to a specific variety or breed.
At the same time, the directive and the rules derived from the EPC reinforced ethical exclusions: patents are not allowed on processes involving the destruction of human embryos, nor on genetic modifications in animals that cause them suffering without substantial medical benefit. In 2008, for example, the EPO’s Enlarged Board of Appeal set a legal precedent in the WARF/Thomson case, denying a patent for a technique that necessarily required the destruction of human embryos to obtain stem cells, considering such an act to be contrary to ethics.
In summary, Europe offers a favorable yet responsible legal framework: it promotes the protection of biotechnological inventions by providing broad territorial coverage and mechanisms such as the European or unitary patent, while imposing clear limits to ensure that patentable activity respects ethical values and the public interest. The EPO, with its specialized team (some 260 examiners dedicated solely to the field of biotechnology), ensures through rigorous examinations that only high-quality patents that truly meet legal requirements are granted, thereby providing legal certainty to innovators and investors.
Notable Examples of Biotechnology Patents in Europe
Over the years, biotechnology patents have been granted (or rejected) that have become notable for their scientific impact or the ethical questions they raised. Some notable examples:
Oncomouse
Harvard’s “Oncomouse” was one of the first transgenic animals created for medical research (it carries an oncogene that causes it to develop cancer rapidly, which is useful for studying the disease). Harvard University filed patent applications in several countries, including Europe. Although it sparked controversy over “patenting animals”, the EPO deemed this transgenic mouse patentable, reasoning that the suffering caused to the animal was justified by the significant potential medical benefit in the fight against cancer.
The Oncomouse patent set a precedent in Europe regarding how to assess the ethical implications of biological inventions: it was granted because it submitted a clear scientific advance, but it left open the public debate on the limits of patenting life. In contrast, the EPO refused another case known as the “Upjohn mouse” (modified to lose its fur), ruling that it caused animal suffering without a significant medical benefit, and emphasizing that not every genetically modified animal is patentable if it does not pass ethical scrutiny.
El Golden Rice
This genetically modified rice, developed to produce beta-carotene (a precursor to vitamin A), is a positive example of how a biotechnology patent can protect an invention with significant social impact. The so-called Golden Rice aims to combat vitamin A deficiency in populations with diets low in that nutrient. In Europe, inventions such as genetically modified plants with beneficial properties (e.g., vitamin-enriched or drought-resistant crops) are patentable provided they are not limited to a specific variety.
Patents on Golden Rice—granted to universities and companies involved in its development—allowed its use to be managed through licensing, so that companies can commercially exploit it while, at the same time, nonprofit organizations distribute it to low-income farmers under certain agreements. This case is often cited as a prime example of green biotechnology protected by patents for humanitarian and sustainability purposes.
Pioneering Biotech Drugs
Several drugs and therapies derived from biotechnology have been protected by patents that spurred their market entry. For example, recombinant human insulin—produced through genetic engineering in bacteria—was patented at the time, allowing pharmaceutical companies to develop and market this vital product for diabetics on a large scale. The same was true for erythropoietin (EPO) to treat anemia and for the first monoclonal antibodies for cancer: their patents not only rewarded investment in R&D but also facilitated licensing agreements that brought these therapies from the laboratory to patients.
Today, fields such as messenger RNA (mRNA) vaccines—which proved crucial in the fight against COVID-19—are protected by numerous patents registered in Europe and around the world, reflecting the importance of protecting life-saving innovations. These patents, however, have sparked debates about equitable access to medicines, with some calling for flexibility (such as compulsory licenses or temporary patent waivers) in situations of global health emergencies.
Patents in Biotechnology and Emerging Technologies (CRISPR and Gene Editing)
A contemporary example is the patent battle surrounding the CRISPR-Cas9 genome-editing technique. Invented in the early 2010s, CRISPR allows for highly precise gene modification and has sparked a race for intellectual property rights among universities and companies. In Europe, the EPO has granted several CRISPR-related patents to both researcher Emmanuelle Charpentier (co-discoverer of the technique) and other groups, although some were the subject of legal challenges over who was the first to invent the technique.
This landmark case demonstrates the enormous strategic value of patents in cutting-edge biotechnology: whoever controls key gene-editing patents will be able to license the technology for applications in healthcare, agriculture, or industry, thereby influencing the future direction of biotechnology. At the same time, it highlights the complexity of assigning rights to inventions created almost simultaneously in different laboratories—a challenge for patent offices and courts.
These examples illustrate how biotechnology patents can be powerful tools for driving innovation (by protecting inventions such as the Oncomouse or golden rice) but can also raise ethical and legal dilemmas. Europe has been building a body of case law and regulations to strike the right balance, on a case-by-case basis, between incentivizing scientific progress and safeguarding ethical principles and the public interest.
Ethical and Legal Challenges of Biotechnology Patents
The field of biotechnology presents unique challenges in terms of intellectual property because it deals with life and nature. Below are some of the most notable ethical and legal challenges associated with biotechnology patents:
Patenting Life: The Fundamental Ethical Debate
Many people question whether it is morally acceptable to patent living beings or their components. The idea of granting exclusive rights over DNA sequences, modified organisms, or isolated human genes raises concerns in certain sectors of society, which view it as a commodification of life. This debate came to the fore in Europe during the drafting of Directive 98/44/EC and in cases such as the Oncomouse case. Authorities have responded by establishing limits (such as excluding the human body, embryos, natural varieties, etc.), but the debate persists over where to draw the line between discovery (which is not patentable) and invention (which may be patentable).
An example: discovering the sequence of a human gene linked to a disease—should this be considered a mere discovery of something that already existed in nature (non-patentable), or, if it is isolated and a diagnostic application is proposed, does it become a patentable invention? Europe has opted for the latter, provided that a specific and useful application of the sequence is indicated, though not without controversy.
Access to Medicines and Biological Resources
Critics of patents argue that granting temporary monopolies on essential products (such as drugs or seeds) can limit the public’s access to vital goods. For example, if a company holds the patent on a crucial drug, it can set high prices that some healthcare systems or patients cannot afford. Similarly, farmers might depend on patented seeds (such as pest-resistant genetically modified varieties) whose cost or usage restrictions could affect their livelihoods.
This access vs. incentive dilemma has no easy solution: patents are necessary for companies to invest in developing these products in the first place, but governments and international organizations are seeking mechanisms (global funds, voluntary licenses, price regulation, etc.) to mitigate the impact on affordability. The COVID-19 pandemic reignited this debate with proposals to temporarily suspend certain vaccine patents for the common good, countered by the argument that doing so could discourage innovation in future emergencies.
Hindering research vs. open disclosure
Another point of debate is whether patents hinder scientific research by restricting the use of techniques or materials patented by third parties. In practice, most legislation (including European law) provides exceptions for the use for experimental purposes of patented inventions, allowing universities and researchers to conduct studies without seeking permission from the patent holder, provided that the search is for non-commercial purposes. Furthermore, as mentioned, every published patent adds to the body of knowledge available to the scientific community.
However, tensions exist, for example, in molecular biotechnology: if an essential tool (such as a gene-editing technique or a diagnostic method) is patented, academic researchers can use it for search, but any attempt to develop a commercial application will require negotiating licenses, which can be complex and costly.
This poses a legal challenge in striking a balance between protecting the invention and ensuring that science can continue to advance. Patent offices try to avoid granting overly broad patents that would block entire areas of research (for example, by refusing patents on basic scientific knowledge or natural phenomena in and of themselves).
Bioethical Considerations at Patent Offices
The EPO and national patent offices sometimes must make decisions that border on bioethics. As we have seen, they have denied patents for inventions that involved destroying human embryos or causing unjustified animal suffering. These decisions seek to align the patent system with the ethical values of European society. However, this is a complex area: the patent office evaluates inventions, not practical actions. For example, patenting a genetic engineering technology does not morally authorize its irresponsible use; it merely protects intellectual property.
In fact, the grant of a patent does not exempt the holder from complying with other laws: a patent does not automatically grant the right to market a product if it requires health or environmental authorizations. For this reason, some argue that ethical considerations should be addressed in specific legislation (e.g., biosafety laws, clinical trial regulations, etc.) rather than by the patent office. Even so, the existence of ethical provisions in patent laws serves as a last-resort filter to prevent the patent system from endorsing inventions that are profoundly contrary to ethics (for example, human clones, the exploitation of embryos, biological weapons, etc.).
In short, the ethical and legal challenges surrounding biotechnology patents require a careful balance. Europe has developed a flexible framework that, supported by case law, seeks to foster innovation without crossing certain moral boundaries or compromising the public interest. The debate remains open and evolves with each new scientific advance, requiring ongoing dialogue among scientists, legal experts, companies, and society.
The Role of Biotechnology Patents in the Future of Health, Agriculture, and Sustainability
Looking ahead, patents will continue to be a pillar for protecting and driving biotechnological innovations in crucial sectors:
Health and Life Sciences
Medical biotechnology (red biotechnology) is breaking new ground in gene therapies, personalized treatments, next-generation vaccines, and cancer immunotherapies, among others. These areas require enormous investments and long development timelines, and therefore patents will be key to ensuring that pharmaceutical and biotechnology companies are encouraged to invest in them. For example, new therapies based on gene editing (such as potential cures for hereditary diseases using CRISPR-like techniques) will need patentable protection to attract the funding needed to take them from the experimental phase to clinical trials.
Likewise, patents will facilitate technology transfer between universities and companies—through licensing—so that laboratory discoveries can be turned into products (medicines, diagnostic kits, biomedical equipment) available on the market. In the near future, we can expect patents in fields such as regenerative medicine (cultured organs, 3D-printed tissues), neurobiotechnology (new drugs or brain-machine interfaces), and advances related to pandemics or antimicrobial resistance.
Protecting these inventions will be synonymous with protecting the future of healthcare, as it incentivizes innovators to tackle major medical challenges knowing that their solutions will be commercially protected.
Agriculture and Sustainable Food
Agricultural biotechnology (green biotechnology) will become even more crucial in the face of the challenge of feeding a growing global population under the threat of climate change. Patents in this field will range from new varieties of genetically modified or gene-edited crops resistant to drought, pests, and extreme conditions, to biofertilizer technologies and biological pest control. A clear example already mentioned is golden rice and other nutritionally enriched grains, but more innovations are on the way: plants capable of fixing atmospheric nitrogen (reducing the need for chemical fertilizers) or crops designed to tolerate saline or poor soils. Similarly, in livestock and aquaculture, genetics and biotechnology will produce animals that are more disease-resistant or have a smaller environmental footprint.
Patents will ensure that the companies and research centers developing these improvements can recoup their investments, thereby stimulating the creation of resilient agricultural solutions. At the same time, these patents will need to be properly managed so that farmers can access these technologies under fair conditions, while maintaining economic and environmental sustainability. In Europe, bioeconomy policy and the CAP (Common Agricultural Policy) will likely include mechanisms to balance patented innovation with support for farmers, ensuring that patents fulfill their purpose without jeopardizing food security.
Environmental Sustainability and Green Energy
So-called white (industrial) and blue (marine) biotechnology submit critical tools for sustainability. This includes microorganisms designed to degrade waste or generate bioenergy, enzymes for producing bioplastics, and algae for capturing CO₂ and producing biofuels, among other advances. For example, bacteria capable of cleaning up oil spills or treating wastewater have already been patented, as have enzymes that improve the efficiency of detergents and industrial processes by reducing energy consumption. Looking ahead, we will see patents on microbial consortia that convert organic waste into useful materials (circular economy), on genetically enhanced algae to absorb atmospheric CO₂, or on new biofuels and biopolymers that replace petroleum-derived products.
All these green inventions require the incentive provided by patents: many environmental biotechnology start-ups are emerging in Europe with promising ideas but need capital to scale up their processes. Patents allow them to protect their know-how and negotiate investments or industrial partnerships with the assurance that their technology will not be immediately replicated by a competitor. Furthermore, sustainability patents can foster international collaboration: public and private entities can share technologies through licensing to spread solutions to climate change globally, while ensuring recognition and benefits for the original inventors.
Patents as Guarantors of the Future
In all these sectors—health, food, and the environment—patents will act as guarantors of the future. Without the protection they provide, many of the biotechnological solutions needed to tackle diseases, hunger, or the climate crisis could fall by the wayside due to a lack of investment or commercial interest. With well-managed patents, these innovations are more likely to come to fruition and translate into concrete benefits for society. That said, the patent system must continue to adapt: for example, by expediting procedures for critical technologies (as was done with COVID-19 vaccines), promoting open-source patents or patent pools in areas where collaboration is essential, and ensuring that ethical considerations and equitable access accompany the drive for innovation.
Recommendations for Leveraging the Patent System in Biotechnology
For entrepreneurs and researchers involved in biotechnology, understanding and effectively using the patent system can make all the difference in the success of their projects—especially if you’re a biotech SME, where active patent portfolio management and technology watch are key. Here are some practical recommendations:
Integrate patent strategy from the outset
Both startups and research groups should consider intellectual property in the early stages of development. Identify which parts of your innovation are patentable and apply for protection early, preferably before disclosing results in publications or at conferences (prior public disclosure can destroy the novelty required for a patent). Having strong patents will turn your scientific advances into tangible commercial assets, increasing the value of your company or project.
Seek Advice from Professionals and Patent Offices
The field of patents can be complex, so it is essential to seek specialized support. Entrepreneurs should rely on patent agents or intellectual property attorneys to draft and file their applications effectively, making the most of all possible claims. Academic researchers can turn to their institutions’ technology transfer offices (OTRI), which typically assist with managing patents derived from research. In addition, consult official sources: the European Patent Office (EPO) and national offices (such as the OEPM in Spain) offer guides, free searches, and sometimes even preliminary advice for inventors. Being well-advised prevents costly mistakes and speeds up the process of obtaining protection.
Use international protection tools
Biotechnology typically has a global market, so think strategically beyond national borders. Take advantage of the European Patent system to protect your invention in multiple European countries with a single application. Also consider the Patent Cooperation Treaty (PCT) to initiate a unified process through the EPO or WIPO that preserves your rights while you decide in which countries to seek patents. And if your business is strongly focused on the European Union (EU) market, evaluate the new Unitary Patent, which simplifies validation in many EU countries with lower translation costs and fees. Protecting a biotechnology invention internationally is an investment, but a necessary one if you intend to exploit or license the technology globally.
Leveraging Technological Information from Patents
Don’t view patents solely as protection, but also as a source of knowledge. Before embarking on a project, conduct searches in patent databases (for example, the EPO’s Espacenet, which is free) to identify the state of the art: what similar solutions exist, what competitors are patenting, and whether your idea is truly novel. This technology watch will prevent you from reinventing the wheel and help you differentiate your innovation. Likewise, reviewing third-party patents can inspire improvements and serve as a technical guide (many patent documents contain valuable experimental details not published in scientific articles). Make patent searching a habit in your R&D work.
Manage Patents as a Business Asset
For entrepreneurs, patents are not just legal documents, but intangible assets that must be managed proactively. Keep your patent portfolio aligned with your business strategy: decide which patents are essential (core) to your technology and protect them rigorously, and consider patenting improvements or secondary applications as well if they add value.
Use patents to negotiate agreements: for example, licensing to larger companies in geographic markets you won’t cover, or public-private partnerships where your patent can be combined with other technologies. Also, keep an eye on the expiration of rival patents to capitalize on opportunities when key technologies become available. And don’t forget to comply with maintenance requirements (annual fee payments) so you don’t lose your rights through negligence.
Consider Ethical and Transparency Issues
In biotechnology, more so than in other sectors, the public acceptance of your product can be just as important as its legal protection. Being transparent about your technology and patents, and acting responsibly with licensing (for example, facilitating access for developing countries or for humanitarian uses when appropriate) can enhance the image of your company or institution. Initiatives such as non-exclusive global licenses during pandemics, or commitments to share patents for charitable purposes, can add reputational value to the project without compromising its basic commercial viability. Remember that a patent grants you the legal right of exclusion, but how you exercise that right is a strategic and ethical decision. Striking a balance between protection and social responsibility often pays off in the long run.
At ISERN, we help you protect biotechnology patents
Biotechnology patents are a powerful tool for protecting the future of innovation. In Europe, the backing of a robust patent system enables entrepreneurs and researchers to transform their discoveries into real-world solutions, with the assurance that they can reap the benefits of their efforts. At the same time, it entails a commitment to use that protection in a way that ensures innovation reaches those who need it. With knowledge, planning, and ethics, the patent system can be the ally that propels your biotechnology developments from the laboratory to society, ensuring that we continue to make progress in health, agriculture, and sustainability for generations to come.
At ISERN, we specialize in patents and trademarks. We protect your innovation by defending and registering patents and trademarks. We design innovative strategies, based on Legaltech, to effectively protect your assets. If you have any questions, feel free to contact us for a no-obligation consultation.